GLOBAL-DAIRY-PLATFORM
11.11.2022 01:02:43 CET | Business Wire | Press release
The dairy sector today announced progress of its global Pathways to Dairy Net Zero (P2DNZ) climate initiative, which was launched last year. The ground-breaking effort is achieving positive results in many regions and accelerating action in others, according to speakers at a COP27 side event, “The Global Dairy Sector’s Climate Ambition and Progress Towards Achievement of the Paris Agreement.”
P2DNZ is backed by more than 140 leading organizations and governments, including the 10 largest dairy companies in the world. Collectively, supporters represent more than 40% of global dairy production throughout the supply chain, making it one of the largest initiatives of its kind in agriculture.
“Dairy is a major force for good in the world, especially when you consider how the sector helps provide important nutrition to the hungry and malnourished and helps build strong, resilient economies, said Hein Schumacher, chair of Global Dairy Platform, one of the founders of Pathways to Dairy Net Zero, and CEO of Royal FrieslandCampina. “By systematically introducing and enhancing climate action in global dairy systems, dairy is tackling the challenge and making progress in reducing our impact on the planet,” he said.
Research is Identifying Practical Pathways for Dairy Systems Worldwide
Research commissioned as part of P2DNZ has identified six primary dairy production systems throughout the world, along with potential mitigation options and their estimated impact on emissions reduction. The research is led by the Global Research Alliance on Agricultural Greenhouse Gases (GRA) in close collaboration with the UN Food and Agriculture Organization (FAO). They have defined the composition of GHGs emitted by the various dairy production systems around the world and learned there is variability by system. For instance, methane is a large proportion of GHGs in pastoral and agropastoral systems, driven largely by enteric fermentation. However, high-input, high-output production emits a different mix of GHGs from not only enteric fermentation but also manure management, animal feed and energy use.
The six dairy production systems include:
- High-input, high-output
- Medium-scale specialized
- Pasture-fed
- Smallholder specialized
- Smallholder dual-purpose
- Pastoral and agropastoral
Researchers are also modeling the impact on warming of cumulative emissions for each GHG. This work is critical because each gas has a different effect and unique longevity in the atmosphere. For instance, while methane is a highly potent GHG it breaks down in the atmosphere in 12 years. Whereas other gases, such as carbon dioxide, can remain in the atmosphere for hundreds of years.
Although mitigation options will vary by each dairy production system, some of the primary pathways include improving animal health, increasing feed digestibility, enhanced manure storage and treatment, more efficient fertilizer use and the potential adoption of methane-inhibiting feed additives.
“Because GRA brings together leading expertise in agricultural GHG emissions, we are pleased to be working on the Pathways to Dairy Net Zero initiative to map emissions and mitigation potential within the diverse range of global dairy production systems,” said Dr. Harry Clark, co-chair of the Livestock Research Group of GRA and co-director of the New Zealand Agricultural Greenhouse Gas Research Centre. “While there are good options emerging for dairy systems in developed countries, our analysis reinforces the importance of developing and implementing appropriate options for regions and systems where the climate, soil and access to markets have limited options,” he said.
Progress in Developed Markets
Dairy companies around the world are reducing their impacts on the environment by improving farming and production practices and developing new technologies. FAO reports that during the period from 2005 – 2015, the global dairy sector’s emission intensity declined by 11%. Dairy farming has become more efficient which is resulting in declining emission intensities per unit of product all over the world. This is especially true in developed dairy markets where emission intensities have declined to between 1.3 to 1.4 kg CO₂ equivalent kg fat-and-protein corrected milk. For comparison, developing dairy regions’ emission intensities can range between 4.1 to 6.7 kg CO₂ equivalent per kg fat-and-protein corrected milk.
Tackling Emissions in Emerging Markets
Many of the best practices that have already been developed are being implemented in emerging dairy countries, where approximately 80% of the global dairy sector’s emissions are generated.
To help facilitate and accelerate these efforts, the global dairy sector, the Global Methane Pledge, FAO and others have invited 10 developing dairy countries to join P2DNZ as “early adopters.” Collectively these countries represent more than 30% of the sector’s global GHG emissions and include (those in bold have already accepted):
- Africa: Tanzania, Kenya, Rwanda, Uganda
- Americas: Uruguay, Costa Rica, Colombia
- Asia: Pakistan, Vietnam, India
For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.
###
About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.
Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.
The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005906/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
